scholarly journals Impact of Dose Algorithm and Calculation Angle Interval on in Vivo Dose Verification of Stereotactic Body Radiation Therapy: A Phantom Study

Author(s):  
Shuxu Zhang ◽  
Songgui Luo ◽  
Hui Yu ◽  
Shengqu Lin ◽  
Weibin Zhou ◽  
...  

Abstract ObjectiveTo investigate the impact of different dose algorithms and calculation angle intervals (DCAI) on the in vivo dose (IVD) verification of small-field arc therapy in stereotactic body radiation therapy (SBRT).MethodsWe made an exit-dose-measuring and positioning device (EDPD) for the SRS MapCHECK (SMC) using polymethyl methacrylate (PMMA). Computed tomography data for the anthropomorphic head phantom, SMC, and EDPD combination were acquired with 1 mm slice thickness and spacing. SBRT partial arc plans were created using an SBRT cone, block, and a small square open field, with a gantry rotation angle of 60°. The dose distribution was calculated using three different dose algorithms [Pencil Beam (PB), CC Convolution (CCC), and Monte Carlo (MC)], with 1 mm isotropic resolution. We also used three different DCAIs (1°, 3°, 5°) with the PB and CCC algorithms to calculate the dose distribution of each plan three times. The uncertainty of each control point for the MC algorithm was set to 1%. The SMC was used to measure the exit dose outside the phantom for IVD verification, the detector plane was located 182.5 mm outside the scan center.ResultsWithin the phantom, the minimum passing rate of 3D gamma analysis (1%/1 mm) for the dose distributions calculated at different DCAIs was 99.1%, and the maximum relative deviation (RD) of the central point dose (CPD) was <0.2%. The average RD of the CPD for IVD verification was about 30% (range 16.71%–50.0%) for PB; -0.36% ± 1.82% (1° DCAI), -3.18% ± 7.83% (3° DCAI), and 3.69% ± 11.56% (1° DCAI) for CCC; and -0.38% ± 0.76 for the MC algorithm. The passing rates of 2D gamma analysis (3%/3 mm) between the predicted exit dose and the IVD were 100% for MC and >90% for the CCC algorithm at 1° DCAI.ConclusionThe DCAI for exit-dose calculations should be ≤1° using the CCC algorithm. Furthermore, among the three algorithms verified in the current study, the MC algorithm showed the highest accuracy, followed by CCC, with the PB algorithm having the worst performance. The PB algorithm is thus not suitable for exit-dose calculation or IVD verification of SBRT.

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 413-413
Author(s):  
Lauren M. Rosati ◽  
Zhi Cheng ◽  
Scott P. Robertson ◽  
Megan N. Kummerlowe ◽  
Amy Hacker-Prietz ◽  
...  

413 Background: The impact of fractionated stereotactic body radiation therapy (SBRT) on patient-reported quality of life (QOL) and physician-reported toxicity in patients with recurrent or locally advanced pancreatic cancer (PCA) was prospectively evaluated. Methods: Forty-two PCA patients were treated with 25-33 Gy using SBRT in 5 fractions on a single-institution study. Both patient- and physician-reported outcomes were evaluated prior to SBRT and 4-6 weeks post-SBRT. Eight outcomes were consistently evaluated among both groups—performance status, fatigue, pain, anorexia, nausea, vomiting, constipation, and diarrhea. Patient-reported QOL metrics were assessed using a 4-point Likert scale on the EORTC QLQ-C30 and QLQ-PAN26, while physician-reported toxicities were graded using the NCI CTCAE version 4.0. Comparisons between those with paired patient- and physician-reported outcomes collected prior to and 4-6 weeks after SBRT were made using the Wilcoxon signed-rank test. Results: Of the 42 patients currently enrolled onto the study, 29 had both patient- and physician-reported outcomes collected prior to and 4-6 weeks after SBRT. Fifty-five percent were female and 83% were Caucasian. The median age at diagnosis was 65.6 years (range, 40.8-86.6). There was no significant impairment of any of the 8 physician-reported toxicities, nor were significant changes observed in patient-reported overall health (p = 0.66) or QOL (p = 0.18) scores following SBRT. Patients felt less worried about their future health (mean change [mD] = -0.45, p = 0.02), and an improvement in feeling less attractive as a result of disease and treatment reached borderline significance (mD= 0.31, p = 0.09). However, patients felt limited in planning activities in advance (mD= 0.45, p = 0.02) and were more constipated (mD= 0.38, p = 0.01) 4-6 weeks post-SBRT. Conclusions: Although the numbers are small, patients with unresectable or locally recurrent PCA do not appear to suffer any detriment of overall health or QOL after receiving a five-day course of SBRT. Moreover, this regimen may lead to a more optimistic point of view on future health and/or level of physical attraction. Clinical trial information: NCT01781728.


2008 ◽  
Vol 35 (4) ◽  
pp. 1440-1451 ◽  
Author(s):  
Q. Jackie Wu ◽  
Danthai Thongphiew ◽  
Zhiheng Wang ◽  
Vira Chankong ◽  
Fang-Fang Yin

Sign in / Sign up

Export Citation Format

Share Document